A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

Mount Sinai School of Medicine, New York

Behavioral Medical Research of Staten Island, Staten Island

Lehigh Valley Hospital, Allentown

Scranton Counseling Center, Scranton

Southeastern PA Medical Institute, Broomall

Suburban Research Associates, Media

University of Pennsylvania, Philadelphia

CRI Worldwide, Philadelphia

Clinical Insights, Glen Burnie

VCU, Richmond

Radiant Research, Greer

Atlanta Center for Medical Research, Atlanta

Clinical Neuroscience Solution, Inc., Jacksonville

Florida Clinical Research Center, Maitland

Medical Research Group of Central Florida, Sanford

Clinical Neuroscience Solutions, Inc, Orlando

Sanitas Research, Coral Gables

Vanderbilt University Medical Center, Nashville

Clinical NeuroScience Solutions, Inc., Memphis

Neurology and Neuroscience Center of Ohio, Toledo

North Star Medical Research, Middleburg Heights

Community Research, Cincinnati

Midwest Clinical Research Center, Dayton

Dean Foundation for Health, Research & Education, Middleton

Psychiatric Medicine Associates, Stokie

AMR Baber Research, Naperville

St Charles Psychiatric Associates, Saint Charles

Lake Charles Clinical Trials, Lake Charles

SP Research, PLLC, Oklahoma City

FutureSearch Trials of Dallas, Dallas

Radiant Research, Inc., Denver

Aspen Clinical Research, Orem

Radiant Research, Inc., Murray

Southwest Research, Inc., Beverly Hills

Pacific Clinical Research Medical Group, Arcadia

Pacific Clinical Research Medical Group, Upland

Synergy Clinical Research Center, National City

Clinical Innovations, Inc., Santa Ana

Comprehensive Psychiatric Care, Norwich

Cambridge Health Alliance, Cambridge

AccelRx Research, Fall River

Global Medical Institutes, Princeton

CRI Worldwide, LLC, Willingboro